|
|
| April 4, 2011: Dr. A Michael Lincoff and Dr. C. Michael Gibson discuss: Selective Inhibition of Delta Protein Kinase C to Reduce Infar |
Dr. A Michael Lincoff and Dr. C. Michael Gibson discuss: Selective Inhibition of Delta
Protein Kinase C to Reduce Infarct Size after Primary Percutaneous Intervention for Acute
Myocardial Infarction: The PROTECTION-AMI Phase IIb Clinical Trial at ACC 2011.
C5Research: Anthera, AstraZeneca, Atherosys, Bristol-Myers Squibb (BMS), Centocor, Cordis,
Guidant, Heartscape, J&K, KAI Pharma, Lilly, Mannkind, Medicines Company, Medtronic,
Novartis, Novo Nordisk, Pfizer, Resverlogix, Roche/Genentech, Sankyo, Sanofi-Aventis,
Schering-Plough, Scios, Takeda, VasoGenix. Consultant: Schering-Plough, Bioline, BMS,
Merck, Baxter, Aztra Zeneca, Roche.
[ Download video ] |
|
No comments have been submitted
|